Tumor-Cell Number and Viability as Quality and Efficacy Parameters of Autologous Virus-Modified Cancer Vaccines in Patients With Breast or Ovarian Cancer

The April 1997 article entitled, "Tumor-Cell Number and Viability as Quality and Efficacy Parameters of Autologous Virus-Modified Cancer Vaccines in Patients With Breast or Ovarian Cancer" by Ahlert et al (J Clin Oncol 15:1354–1366, 1997) contained several errors. On page 1354, the affiliation should have read: from the Universitat-Frauenklinik Heidelberg; Deutsches Krebsforschungszentrum Heidelberg, Abteilung 710; Forschungspraxis Technologiepark Heidelburg; Institute fur medizinische Biometrie und Informatik, Universitat Freiburg, Freiburg, Germany. Reference number 36 on page 1365 should have read: 36. Pomer S, Schirrmacher V, Thiele R, et al: Tumor response and 4-year survival data of patients with advanced renal cell carcinoma treated with autologous tumor vaccine and subcutaneous r-IL-2 and IFN-alpha 2b. Int J Oncol 6:941–954, 1995 In addition, Table 5 is reprinted here correctly in its entirety: Please see the PDF for table 5.

[1]  J. Allison,et al.  Enhancement of Antitumor Immunity by CTLA-4 Blockade , 1996, Science.

[2]  E. Stoelben,et al.  Newcastle disease virus-infected intact autologous tumor cell vaccine for adjuvant active specific immunotherapy of resected colorectal carcinoma. , 1995, Clinical cancer research : an official journal of the American Association for Cancer Research.

[3]  V. Schirrmacher.  Tumor vaccine design: concepts, mechanisms, and efficacy testing. , 1995, International Archives of Allergy and Immunology.

[4]  M. Mitchell,et al.  Active specific immunotherapy of melanoma. , 1990, British medical bulletin.

[5]  K. Bland,et al.  A phase III randomized, doúble‐blind, multiinstitutional trial of vaccinia melanoma oncolysate‐active specific immunotherapy for patients with stage II melanoma , 1995, Cancer.

[6]  I. Gresser,et al.  Successful immunotherapy of the highly metastatic murine ESb lymphoma with sensitized CD8+ T cells and IFN‐α/β , 1994 .

[7]  M. Colombo,et al.  Cytokine gene transfer in tumor inhibition and tumor therapy: where are we now? , 1994, Immunology today.

[8]  N. Millar,et al.  Viral hemagglutinin augments peptide‐specific cytotoxic T cell responses , 1993, European journal of immunology.

[9]  B. Gückel,et al.  Tumour‐Specific CTL response requiring interactions of four different cell types and recognition of MHC class I and class II restricted tumour antigens , 1993, Immunology and cell biology.

[10]  F. Miller,et al.  Induction of antitumor immunity by interleukin-2 gene-transduced mouse mammary tumor cells versus transduced mammary stromal fibroblasts. , 1993, Journal of the National Cancer Institute.

[11]  M. Hanna,et al.  Adjuvant active specific immunotherapy for human colorectal cancer: 6.5-year median follow-up of a phase III prospectively randomized trial. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  S. Rosenberg,et al.  A nonimmunogenic sarcoma transduced with the cDNA for interferon gamma elicits CD8+ T cells against the wild-type tumor: correlation with antigen presentation capability , 1992, The Journal of experimental medicine.

[13]  V. Schirrmacher.  Immunity and metastasis: in situ activation of protective T cells by virus modified cancer vaccines. , 1992, Cancer surveys.

[14]  D. Pardoll.  New strategies for active immunotherapy with genetically engineered tumor cells. , 1992, Current opinion in immunology.

[15]  P. Schlag,et al.  In vitro and clinical characterisation of a Newcastle disease virus-modified autologous tumour cell vaccine for treatment of colorectal cancer patients. , 1991, European journal of cancer.

[16]  J. Sinkovics.  Viral oncolysates as human tumor vaccines. , 1991, International reviews of immunology.

[17]  V. Schirrmacher,et al.  Isolation of a human melanoma adapted Newcastle disease virus mutant with highly selective replication patterns. , 1990, Cancer research.

[18]  J. Wharton,et al.  T-cell functions in ovarian cancer patients treated with viral oncolysates: I. Increased helper activity to immunoglobulins production. , 1990, Anticancer research.

[19]  M. J. Ehrke,et al.  Effects of anticancer drugs on the immune system in humans. , 1989, Seminars in oncology.

[20]  P. Altevogt,et al.  Prevention of metastatic spread by postoperative immunotherapy with virally modified autologous tumor cells. III. Postoperative activation of tumor-specific CTLP from mice with metastases requires stimulation with the specific antigen plus additional signals. , 1989, Invasion and Metastasis.

[21]  R. Cantrell,et al.  Indomethacin sensitive suppressor‐cell activity in head and neck cancer patients: The role of the adherent mononuclear cell , 1988, Cancer.

[22]  E. Henshaw,et al.  Inhibition of suppressor T lymphocytes (Ts) by cimetidine. , 1987, Journal of immunology.

[23]  B. Matouš,et al.  Postoperative active specific immunotherapy with supportive measures in patients suffering from recurrent metastasized melanoma: Case reports of six patients , 1986, Journal of surgical oncology.

[24]  R. Heicappell,et al.  Prevention of metastatic spread by postoperative immunotherapy with virally modified autologous tumor cells. I. Parameters for optimal therapeutic effects , 1986, International journal of cancer.

[25]  J. Murray,et al.  In vitro inhibition of interleukin-2 production by peripheral blood lymphocytes from stage III melanoma patients by prostaglandin E2: enhancement of lymphocyte proliferation by exogenous interleukin-2 plus indomethacin. , 1986, Journal of biological response modifiers.

[26]  K. Melmon,et al.  Pharmacologic effects of autacoids on subsets of T cells. Regulation of expression/function of histamine-2 receptors by a subset of suppressor cells. , 1985, The Journal of clinical investigation.

[27]  S. Sarna,et al.  Active specific immunotherapy with supportive measures in the treatment of palliatively nephrectomized, renal adenocarcinoma patients. A thirteen-year follow-up study. , 1985, European urology.

[28]  M. Hanna,et al.  Delayed cutaneous hypersensitivity to autologous tumor cells in colorectal cancer patients immunized with an autologous tumor cell: Bacillus Calmette-Guérin vaccine. , 1984, Cancer research.

[29]  D. Murray,et al.  A phase II study on the postsurgical management of stage II malignant melanoma with a Newcastle disease virus oncolysate , 1983, Cancer.

[30]  David R. Cox,et al.  Regression models and life tables (with discussion , 1972 .

[31]  G. Klein,et al.  Demonstration of resistance against methylcholanthrene-induced sarcomas in the primary autochthonous host. , 1960, Cancer research.

[32]  E. Kaplan,et al.  Nonparametric Estimation from Incomplete Observations , 1958 .